Cargando…

Clinical outcomes of stereotactic magnetic resonance image‐guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis

PURPOSE: Stereotactic body radiotherapy (SBRT) delivers ablative doses with excellent local control. However, implementing SBRT for abdominal and pelvic tumors has been limited by the risk for treatment‐related gastrointestinal toxicity. MRI‐guided radiotherapy may ameliorate these risks and increas...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Stephanie M., Luterstein, Elaine, Chu, Fang‐I, Cao, Minsong, Lamb, James, Agazaryan, Nzhde, Low, Daniel, Raldow, Ann, Steinberg, Michael L., Lee, Percy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419771/
https://www.ncbi.nlm.nih.gov/pubmed/34288538
http://dx.doi.org/10.1002/cam4.4139
_version_ 1783748821260435456
author Yoon, Stephanie M.
Luterstein, Elaine
Chu, Fang‐I
Cao, Minsong
Lamb, James
Agazaryan, Nzhde
Low, Daniel
Raldow, Ann
Steinberg, Michael L.
Lee, Percy
author_facet Yoon, Stephanie M.
Luterstein, Elaine
Chu, Fang‐I
Cao, Minsong
Lamb, James
Agazaryan, Nzhde
Low, Daniel
Raldow, Ann
Steinberg, Michael L.
Lee, Percy
author_sort Yoon, Stephanie M.
collection PubMed
description PURPOSE: Stereotactic body radiotherapy (SBRT) delivers ablative doses with excellent local control. However, implementing SBRT for abdominal and pelvic tumors has been limited by the risk for treatment‐related gastrointestinal toxicity. MRI‐guided radiotherapy may ameliorate these risks and increase the therapeutic ratio. We report the clinical outcomes of stereotactic MRI‐guided adaptive radiotherapy (SMART) for primary and metastatic tumors in the abdomen and pelvis. METHODS: From November 2014 to August 2017, the first 106 consecutive patients with 121 tumors in the abdomen and pelvis were treated with SMART at a single institution. Of the cohort, 41.5%, 15.1%, and 43.4% had primary, locally recurrent, and oligometastatic tumors, respectively. SMART was delivered using a tri‐cobalt‐60 gantry with on‐board 0.35 Tesla MRI with respiratory breath‐hold and daily adaptive re‐planning when anatomically necessary. A median of 40Gy in five fractions was prescribed. The Common Terminology Criteria for Adverse Events v.4.03 was used to score treatment‐related toxicities. Local control (LC), progression‐free survival (PFS), and overall survival (OS) were estimated using Kaplan–Meier method. RESULTS: Of the 510 treatments, seventy‐one (13.9%) were adapted. Fatigue, nausea, and pain were the most common acute toxicities. 0.9 and 0% of patients experienced acute grade three and four toxicities, respectively. 5.2 and 2.1% of patients experienced late grade three and four toxicities, respectively. After a median follow‐up of 20.4 months, the 2‐year LC rate was 74% on a per‐lesion basis. Two‐year LC was 96% for lesions that were treated with BED(10)≥100 versus 69% for BED(10)<100 (p = 0.02). PFS was significantly different between patients with and without locally controlled tumors (2‐year PFS 21 vs. 8%, p = 0.03). Two‐year OS was 57% for the entire cohort. CONCLUSIONS: Favorable LC and PFS outcomes were observed with minimal morbidity for tumors in the abdomen and pelvis treated with SMART. Future prospective clinical trials to validate these findings are warranted.
format Online
Article
Text
id pubmed-8419771
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84197712021-09-08 Clinical outcomes of stereotactic magnetic resonance image‐guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis Yoon, Stephanie M. Luterstein, Elaine Chu, Fang‐I Cao, Minsong Lamb, James Agazaryan, Nzhde Low, Daniel Raldow, Ann Steinberg, Michael L. Lee, Percy Cancer Med Clinical Cancer Research PURPOSE: Stereotactic body radiotherapy (SBRT) delivers ablative doses with excellent local control. However, implementing SBRT for abdominal and pelvic tumors has been limited by the risk for treatment‐related gastrointestinal toxicity. MRI‐guided radiotherapy may ameliorate these risks and increase the therapeutic ratio. We report the clinical outcomes of stereotactic MRI‐guided adaptive radiotherapy (SMART) for primary and metastatic tumors in the abdomen and pelvis. METHODS: From November 2014 to August 2017, the first 106 consecutive patients with 121 tumors in the abdomen and pelvis were treated with SMART at a single institution. Of the cohort, 41.5%, 15.1%, and 43.4% had primary, locally recurrent, and oligometastatic tumors, respectively. SMART was delivered using a tri‐cobalt‐60 gantry with on‐board 0.35 Tesla MRI with respiratory breath‐hold and daily adaptive re‐planning when anatomically necessary. A median of 40Gy in five fractions was prescribed. The Common Terminology Criteria for Adverse Events v.4.03 was used to score treatment‐related toxicities. Local control (LC), progression‐free survival (PFS), and overall survival (OS) were estimated using Kaplan–Meier method. RESULTS: Of the 510 treatments, seventy‐one (13.9%) were adapted. Fatigue, nausea, and pain were the most common acute toxicities. 0.9 and 0% of patients experienced acute grade three and four toxicities, respectively. 5.2 and 2.1% of patients experienced late grade three and four toxicities, respectively. After a median follow‐up of 20.4 months, the 2‐year LC rate was 74% on a per‐lesion basis. Two‐year LC was 96% for lesions that were treated with BED(10)≥100 versus 69% for BED(10)<100 (p = 0.02). PFS was significantly different between patients with and without locally controlled tumors (2‐year PFS 21 vs. 8%, p = 0.03). Two‐year OS was 57% for the entire cohort. CONCLUSIONS: Favorable LC and PFS outcomes were observed with minimal morbidity for tumors in the abdomen and pelvis treated with SMART. Future prospective clinical trials to validate these findings are warranted. John Wiley and Sons Inc. 2021-07-20 /pmc/articles/PMC8419771/ /pubmed/34288538 http://dx.doi.org/10.1002/cam4.4139 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Yoon, Stephanie M.
Luterstein, Elaine
Chu, Fang‐I
Cao, Minsong
Lamb, James
Agazaryan, Nzhde
Low, Daniel
Raldow, Ann
Steinberg, Michael L.
Lee, Percy
Clinical outcomes of stereotactic magnetic resonance image‐guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis
title Clinical outcomes of stereotactic magnetic resonance image‐guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis
title_full Clinical outcomes of stereotactic magnetic resonance image‐guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis
title_fullStr Clinical outcomes of stereotactic magnetic resonance image‐guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis
title_full_unstemmed Clinical outcomes of stereotactic magnetic resonance image‐guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis
title_short Clinical outcomes of stereotactic magnetic resonance image‐guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis
title_sort clinical outcomes of stereotactic magnetic resonance image‐guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419771/
https://www.ncbi.nlm.nih.gov/pubmed/34288538
http://dx.doi.org/10.1002/cam4.4139
work_keys_str_mv AT yoonstephaniem clinicaloutcomesofstereotacticmagneticresonanceimageguidedadaptiveradiotherapyforprimaryandmetastatictumorsintheabdomenandpelvis
AT lutersteinelaine clinicaloutcomesofstereotacticmagneticresonanceimageguidedadaptiveradiotherapyforprimaryandmetastatictumorsintheabdomenandpelvis
AT chufangi clinicaloutcomesofstereotacticmagneticresonanceimageguidedadaptiveradiotherapyforprimaryandmetastatictumorsintheabdomenandpelvis
AT caominsong clinicaloutcomesofstereotacticmagneticresonanceimageguidedadaptiveradiotherapyforprimaryandmetastatictumorsintheabdomenandpelvis
AT lambjames clinicaloutcomesofstereotacticmagneticresonanceimageguidedadaptiveradiotherapyforprimaryandmetastatictumorsintheabdomenandpelvis
AT agazaryannzhde clinicaloutcomesofstereotacticmagneticresonanceimageguidedadaptiveradiotherapyforprimaryandmetastatictumorsintheabdomenandpelvis
AT lowdaniel clinicaloutcomesofstereotacticmagneticresonanceimageguidedadaptiveradiotherapyforprimaryandmetastatictumorsintheabdomenandpelvis
AT raldowann clinicaloutcomesofstereotacticmagneticresonanceimageguidedadaptiveradiotherapyforprimaryandmetastatictumorsintheabdomenandpelvis
AT steinbergmichaell clinicaloutcomesofstereotacticmagneticresonanceimageguidedadaptiveradiotherapyforprimaryandmetastatictumorsintheabdomenandpelvis
AT leepercy clinicaloutcomesofstereotacticmagneticresonanceimageguidedadaptiveradiotherapyforprimaryandmetastatictumorsintheabdomenandpelvis